GlaxoSmithKline and Johnson & Johnson returned to join Sanofi in backing the biopharmaceutical company's series B round, bringing its total funding to more than $65m.

US-based biopharmaceutical company Navitor Phatmaceuticals has closed a $33m series B round co-led by Brace Pharma Capital, which acts as a subsidiary of Brazil-based pharmaceutical firm EMS, and undisclosed high net worth investors.

The round also included Sanofi-Genzyme BioVentures, Johnson & Johnson Innovation – JJDC and SR One, the respective corporate venturing arms of pharmaceutical companies Sanofi, Johnson & Johnson and GlaxoSmithKline.

Venture capital firms Polaris Partners, Atlas Venture and Remeditex Ventures also took part in the round.

Navitor is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?